The objective of our study is to evaluate the clinical response,
steroid-sparing and adverse affects of long-term
intravenous immunoglobulin (
IVIG) treatment for
autoimmune diseases. Patients were recruited from the Rheumatology clinic. All patients fulfilled the ACR criteria for the appropriate
autoimmune disease. Beneficial effects of
IVIG therapy in
systemic lupus erythematosus (SLE) patients were evaluated utilizing the SLEDAI score. Clinical remission in patients with other
autoimmune diseases was evaluated by a rheumatologist. Data were retrieved retrospectively from an
IVIG database (Excel program). Seventeen patients-SLE (n = 11) and other
autoimmune diseases (n = 6)-received a high dose
IVIG protocol monthly for 6 months, followed by
therapy every 2-3 months. The patients received a mean of 7.9 courses/patient. The mean follow-up for long-term
therapy was 30 months. The response to
IVIG treatment was remission in 12 patients. Change in the SLEDAI score following
IVIG therapy was significant (p < 0.05). In responders,
IVIG harbored a significant
steroid-sparing effect (p < 0.05). Mild and transient adverse effects persisted with long-term
therapy in 50% of patients. Severe adverse effects (
pulmonary embolism and
seizures) occurred early in two patients with SLE and secondary
anti-phospholipid syndrome. Long-term
IVIG therapy is beneficial and carries a good safety profile for SLE and other
autoimmune diseases.